{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:24:30Z","timestamp":1777555470373,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Diabetes Sci Technol"],"published-print":{"date-parts":[[2013,9]]},"abstract":"\n Aims:<\/jats:title>\n Little is known about routine use of basal insulins [glargine, detemir, neutral protamine Hagedorn (NPH)] in primary care patients with type 2 diabetes. The aim was to compare injection frequencies of basal insulins in type 2 diabetes in primary care practices, both for basal-supported oral therapy (BOT) and basal-bolus treatment [intensified conventional therapy (ICT)] regimens.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Primary care data from 4211 glargine (BOT\/ICT, 2247\/1964), 1290 detemir (490\/800), and 3876 NPH (1331\/2425) insulin users were retrospectively analyzed (Disease Analyzer database, May 2009-April 2012). Logistic regression (>1 daily injection) and propensity scores were used to adjust for various confounders (age, sex, type of physician, dosage, body mass index, glycosylated hemoglobin).<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Overall, >1 daily injections were observed in 7.5% of glargine users (BOT, 6.2%; ICT, 9.0%), which was lower than for detemir (overall, 25.4%; BOT, 22.0%; ICT, 27.4%) and NPH (25.4%; BOT, 23.9%; ICT, 27.2%) insulin (all p < .001). The adjusted odds of having >1 injection was lower for glargine compared with detemir (odds ratio, 0.26; 95% CI 0.22\u20130.32) and NPH-insulin (0.20; 0.17\u20130.23). Similar results were found for BOT or ICT and after propensity score matching.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Glargine is associated with significantly lower injection frequencies than other basal insulins. These findings might impact patient-reported outcomes, quality of life, treatment satisfaction, and economic aspects of diabetes treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/193229681300700527","type":"journal-article","created":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T04:08:33Z","timestamp":1421381313000},"page":"1354-1358","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Different Injection Frequencies of Basal Insulins in Type 2 Diabetes Patients under Real-Life Conditions: A Retrospective Database Analysis"],"prefix":"10.1177","volume":"7","author":[{"given":"Wolfgang","family":"Rathmann","sequence":"first","affiliation":[{"name":"Institute of Biometrics and Epidemiology, German Diabetes Center, Duesseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz W.","family":"Dippel","sequence":"additional","affiliation":[{"name":"Sanofi Deutschland GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[{"name":"IMS HEALTH, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"bibr1-193229681300700527","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2008.0023"},{"key":"bibr2-193229681300700527","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1222595"},{"key":"bibr3-193229681300700527","doi-asserted-by":"publisher","DOI":"10.3111\/13696990802645726"},{"key":"bibr4-193229681300700527","first-page":"8","author":"Pscherer S","year":"2010","journal-title":"Ger Med Sci"},{"key":"bibr5-193229681300700527","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47617"},{"key":"bibr6-193229681300700527","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"bibr7-193229681300700527","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0911-x"},{"key":"bibr8-193229681300700527","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.001"},{"key":"bibr9-193229681300700527","doi-asserted-by":"publisher","DOI":"10.5414\/CPP48129"},{"key":"bibr10-193229681300700527","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2001.00529.x"},{"key":"bibr11-193229681300700527","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehrm.2011.02.001"},{"key":"bibr12-193229681300700527","doi-asserted-by":"publisher","DOI":"10.5414\/CP201572"}],"container-title":["Journal of Diabetes Science and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/193229681300700527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/193229681300700527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:10:24Z","timestamp":1777399824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/193229681300700527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1177\/193229681300700527"],"URL":"https:\/\/doi.org\/10.1177\/193229681300700527","relation":{},"ISSN":["1932-2968","1932-2968"],"issn-type":[{"value":"1932-2968","type":"print"},{"value":"1932-2968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}